Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
Condition: Post Partum Depression Interventions: Drug: Ketamine 0.5 mg/kg; Drug: Ketamine 0.2 mg/kg Sponsor: The University of Texas Health Science Center, Houston Recruiting
Conditions: Cigarette Smoking; Current Smoker Interventions: Other: Educational Intervention; Other: Questionnaire Administration; Behavioral: Smoking Cessation Intervention Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); National Institute on Drug Abuse (NIDA) Recruiting
Condition: Post-traumatic Stress Disorder Intervention: Behavioral: Neurofeedback Sponsors: VA Office of Research and Development; Baylor College of Medicine Recruiting
Condition: Obstructive Sleep Apnea Interventions: Procedure: Oxygen Therapy; Other: Questionnaire Administration; Device: Optiflow THRIVE Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Breast Carcinoma; Mammoplasty Patient Interventions: Other: Diary; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Blasts More Than 5 Percent of Bone Marrow Nucleated Cells; Chronic Myelomonocytic Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Recurrent Myelodysplastic Syndrome; Refractory High Risk Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome Interventions: Drug: Azacitidine; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Cancer Survivor; Cranial Nerve Disorder; Head and Neck Carcinoma Interventions: Drug: Methylprednisolone; Drug: Prednisone; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Cognitive Impairment; Creativity Intervention: Behavioral: Musical arts intervention Sponsors: William Marsh Rice University; Methodist Research Institute: Center for Performing Arts Medicine; National Endowment for the Arts; Musiqa Recruiting
Conditions: Chemotherapy-Induced Peripheral Neuropathy; Malignant Neoplasm Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Transcranial Direct Current Stimulation Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: KRAS Gene Mutation; Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 Interventions: Drug: Binimetinib; Drug: Hydroxychloroquine Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Nonalcoholic Fatty Liver Disease; Physician Interventions: Other: Interview; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Frailty Interventions: Behavioral: Meals plus exercise; Behavioral: Meals only Sponsor: The University of Texas Health Science Center, Houston Recruiting
Condition: Invasive Breast Carcinoma Interventions: Other: Interview; Other: Medical Chart Review; Behavioral: Questionnaire Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: High-Frequency Microsatellite Instability; Locally Advanced Malignant Solid Neoplasm; Loss of MLH1 Expression; Loss of MSH2 Expression; Loss of MSH6 Expression; Loss of PMS2 Expression; Mismatch Repair Protein Deficiency Intervention: Biological: Pembrolizumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Acute Myeloid Leukemia in Remission; FLT3 Gene Mutation; Hematologic and Lymphocytic Disorder; High Risk Acute Myeloid Leukemia; Minimal Residual Disease Persistence; Therapy-Related Acute Myeloid Leukemia Interventions: Drug: Azacitidine; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Genentech, Inc. Recruiting
Conditions: Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma Intervention: Drug: Low Dose Radiation Therapy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Solid Neoplasm Interventions: Device: Shear Wave Elastography; Procedure: Tumor Interstitial Fluid Pressure Measurement Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Kidney Injury; Proteinuria; Hypertension Interventions: Drug: Isosorbide Mononitrate; Drug: Placebo oral tablet Sponsors: The University of Texas Health Science Center, Houston; National Kidney Foundation Recruiting
Conditions: Acute Myeloid Leukemia; Blasts 20 Percent or More of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory High Risk Myelodysplastic Syndrome Interventions: Drug: Cladribine; Drug: Cytarabine; Drug: Idarubicin; Drug: Quizartinib Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Laryngeal Squamous Cell Carcinoma; Stage II Laryngeal Cancer AJCC v8; Stage III Laryngeal Cancer AJCC v8 Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Docetaxel; Biological: Pembrolizumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Cognitive Impairment; Breast Cancer Intervention: Behavioral: computer-assisted rehabilitation Sponsor: Texas Woman's University Recruiting
Condition: Breast Carcinoma Interventions: Other: Best Practice; Other: Medical Chart Review; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Supportive Care Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Genentech, Inc. Recruiting
Conditions: Advanced Malignant Solid Neoplasm; Metastatic Carcinoma in the Liver; Metastatic Carcinoma in the Lung; Metastatic Malignant Neoplasm in the Thoracic Cavity; Metastatic Malignant Solid Neoplasm Interventions: Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156; Biological: Ipilimumab; Biological: Nivolumab; Radiation: Stereotactic Body Radiation Therapy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Osteo Arthritis Knee Interventions: Device: Cranial Electrical Stimulation (CES); Device: Sham-CES Sponsor: The University of Texas Health Science Center, Houston Recruiting
Conditions: Body Mass Index Greater Than or Equal to 30; Malignant Breast Neoplasm; Mammoplasty Patient; Obesity Interventions: Procedure: Negative Pressure Wound Therapy; Procedure: Wound Care Management Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Liver and Intrahepatic Bile Duct Carcinoma Interventions: Radiation: Computed Tomography Perfusion Imaging; Procedure: Liver Biopsy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Breast Carcinoma; Mammoplasty Patient Interventions: Procedure: Mammoplasty; Procedure: Vascularized Lymph Node Transfer Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Malignant Neoplasm; Pain Interventions: Other: Medical Chart Review; Other: Survey Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8 Interventions: Radiation: Hypofractionated Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Health Status Unknown; Healthy Subject Interventions: Procedure: Magnetic Resonance Imaging; Procedure: Magnetic Resonance Spectroscopic Imaging Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Recurrent Cervical Carcinoma; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Vaginal Carcinoma; Stage IV Cervical Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IV Vaginal Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVA Vaginal Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8; Stage IVB Vaginal Cancer AJCC v8 Interventions: Procedure: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Talazoparib Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Brain Mass; Glioma Interventions: Procedure: Functional Magnetic Resonance Imaging; Procedure: Magnetic Resonance Imaging; Procedure: Resting State Functional Connectivity Magnetic Resonance Imaging Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Meningioma Interventions: Procedure: Computed Tomography; Radiation: Gallium Ga 68-DOTATATE; Procedure: Positron Emission Tomography Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Melanoma; No Evidence of Disease Interventions: Dietary Supplement: Dietary Intervention; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Advanced Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Neoplasm; Unresectable Carcinoid Tumor Interventions: Drug: Everolimus; Drug: Lenvatinib Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Glioblastoma Interventions: Procedure: Computed Tomography; Other: Fluciclovine F18; Procedure: Positron Emission Tomography Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Anxiety Disorders; Depression; Psychological Distress; Tobacco Dependence; Smoking, Tobacco; Smoking, Cigarette Interventions: Behavioral: PFI for Smoking & Distress Tolerance; Behavioral: PFI for Smoking Only Sponsors: University of Houston; National Institute on Drug Abuse (NIDA) Recruiting
Conditions: Obesity; Anxiety Sensitivity; Eating; Physical Activity Interventions: Other: Anxiety Sensitivity Training; Other: Health Control Sponsor: University of Houston Recruiting
Conditions: Anxiety Disorder; PTSD; Depressive Symptoms; Anger; Depressive Disorder Intervention: Behavioral: Cognitive Behavioral Therapy Sponsors: Baylor College of Medicine; American National Red Cross Recruiting
Conditions: Blasts 10-19 Percent of Bone Marrow Nucleated Cells; Blasts More Than 5 Percent of Bone Marrow Nucleated Cells; High Risk Chronic Myelomonocytic Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory High Risk Myelodysplastic Syndrome Intervention: Drug: Liposome-encapsulated Daunorubicin-Cytarabine Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Multiple Organ Failure; Septic Shock; Severe Sepsis Interventions: Other: Best Practice; Dietary Supplement: early metabolic resuscitation Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Cancer Survivor; Caregiver; Family Member; Health Care Provider; Thyroid Gland Medullary Carcinoma Interventions: Other: Decision Aid; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Type 2 Diabetes Mellitus; Hypogonadism Interventions: Drug: Testosterone gel 1.62%; Drug: Placebo Sponsor: VA Office of Research and Development Recruiting
Conditions: Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma Interventions: Drug: Trabectedin; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Acute Ischemic Stroke Interventions: Device: Endovascular thrombectomy with stent retrievers: Trevo®, Solitaire®, and EmboTrap Revascularization Device; Other: Medical Management Sponsors: The University of Texas Health Science Center, Houston; Stryker Neurovascular Recruiting
Conditions: Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Inflammatory Breast Carcinoma; Progesterone Receptor Negative; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma Interventions: Drug: Atorvastatin; Drug: Capecitabine Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Squamous Cell Carcinoma in Cervical Lymph Node Interventions: Procedure: Computed Tomography; Radiation: Fluciclovine F18; Procedure: Positron Emission Tomography Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Primary Brain Neoplasm Interventions: Drug: Hyperpolarized Carbon C 13 Pyruvate; Procedure: Magnetic Resonance Spectroscopic Imaging Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 Interventions: Drug: Abiraterone Acetate; Drug: Apalutamide; Drug: Prednisone Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Anxiety Disorders Interventions: Behavioral: Intensive Cognitive Behavior Therapy (iCBT); Behavioral: Standard Cognitive Behavior Therapy (sCBT) Sponsor: VA Office of Research and Development Recruiting
Conditions: Advanced Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Ovarian Carcinoma; Refractory Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 Intervention: Drug: TRPV6 Calcium Channel Inhibitor SOR-C13 Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; MKI67 Positive; Postmenopausal; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Drug: Hydroxychloroquine; Drug: Letrozole; Drug: Palbociclib Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Pancreatic Carcinoma Interventions: Other: Best Practice; Drug: Quadratus Lumborum Block; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Malignant Neoplasm; Metastatic Malignant Neoplasm in the Brain Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Stereotactic Radiosurgery Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Recurrent Breast Carcinoma; TP53 wt Allele; Unresectable Malignant Solid Neoplasm Interventions: Drug: MDM2/MDMX Inhibitor ALRN-6924; Drug: Paclitaxel Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Blasts 5 Percent or More of Bone Marrow Nucleated Cells; CD22 Positive; Philadelphia Chromosome Positive; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia Intervention: Biological: ADCT-602 Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); ADC Therapeutics S.A. Recruiting
Conditions: Malignant Neoplasm; Metastatic Malignant Neoplasm in the Brain Intervention: Procedure: Dual-Energy Computed Tomography Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Liver and Intrahepatic Bile Duct Disorder Interventions: Behavioral: BrainCheck Cognitive Assessment; Procedure: Cognitive Assessment Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Blasts More Than 10 Percent of Bone Marrow Nucleated Cells; Blasts More Than 10 Percent of Peripheral Blood White Cells; CD33 Positive; Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia Interventions: Drug: Gemtuzumab Ozogamicin; Drug: Liposome-encapsulated Daunorubicin-Cytarabine; Other: Quality-of-Life Assessment Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Parkinson Disease Interventions: Drug: PRIM-DJ2727; Drug: Placebo oral capsule Sponsors: The University of Texas Health Science Center, Houston; Kelsey Research Foundation Recruiting
Conditions: Acute Myeloid Leukemia; Blasts More Than 10 Percent of Bone Marrow Nucleated Cells; Blasts More Than 10 Percent of Peripheral Blood White Cells; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; TP53 Gene Deletion; TP53 Gene Mutation Interventions: Drug: Decitabine; Drug: Quizartinib; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Malignant Neoplasm Intervention: Other: Survey Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Stroke; Depression; Anxiety Interventions: Behavioral: I'm Whole; Other: Education + usual care Sponsor: VA Office of Research and Development Recruiting
Conditions: Anorexia; Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 Interventions: Drug: Anamorelin Hydrochloride; Other: Placebo; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Human Papillomavirus-Related Carcinoma; Human Papillomavirus-Related Cervical Carcinoma; Stage IB2 Cervical Cancer AJCC v8; Stage II Cervical Cancer AJCC v8; Stage II Vaginal Cancer AJCC v8; Stage IIA Cervical Cancer AJCC v8; Stage IIA Vaginal Cancer AJCC v8; Stage IIA1 Cervical Cancer AJCC v8; Stage IIA2 Cervical Cancer AJCC v8; Stage IIB Cervical Cancer AJCC v8; Stage IIB Vaginal Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Vaginal Cancer AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Vaginal Cancer AJCC v8 Interventions: Radiation: Internal Radiation Therapy; Procedure: Magnetic Resonance Imaging Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Lung Non-Small Cell Carcinoma; Pulmonary Nodule; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8 Interventions: Other: Best Practice; Biological: Pembrolizumab; Other: Quality-of-Life Assessment Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Smoldering Plasma Cell Myeloma Interventions: Procedure: Biopsy Specimen Radiography; Biological: Vaccine Therapy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8 Intervention: Drug: Anti-PD-L1/TGFbetaRII Fusion Protein M7824 Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Glioblastoma Multiforme; Astrocytoma, Grade III Intervention: Drug: ADV/HSV-tk (gene therapy) Sponsors: David Baskin MD; Center for Cell and Gene Therapy, Baylor College of Medicine Recruiting
Conditions: ENSAT Stage I Adrenal Cortex Carcinoma; ENSAT Stage II Adrenal Cortex Carcinoma; ENSAT Stage III Adrenal Cortex Carcinoma Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Mitotane; Procedure: Quality-of-Life Assessment Sponsors: M.D. Anderson Cancer Center; Amercian Australian Asian Adrenal Alliance (A5); European Network for the Study of Adrenal Tumors (ENS@T) Recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Metastatic Triple-Negative Breast Carcinoma; Progesterone Receptor Negative; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Drug: Anti-PD-L1/TGFbetaRII Fusion Protein M7824; Drug: Eribulin Mesylate Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Neurogenic Bladder; Multiple Sclerosis; Voiding Dysfunction Intervention: Device: Transcranial Rotating Permanent Magnet Stimulator (TRPMS) Sponsors: Rose Khavari, M.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting
Conditions: Advanced Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Resectable Head and Neck Squamous Cell Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 Intervention: Biological: Cemiplimab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Malignant Neoplasms of Female Genital Organs Interventions: Drug: Fulvestrant; Drug: Abemaciclib Sponsors: M.D. Anderson Cancer Center; AstraZeneca; Eli Lilly and Company Recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Drug: Bintrafusp Alfa; Radiation: Radiation Therapy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Major Depressive Disorder Interventions: Biological: S.typhi Injection; Biological: Normal Saline Injection Sponsor: The University of Texas Health Science Center, Houston Recruiting
Condition: Mammoplasty Patient Interventions: Other: Questionnaire Administration; Procedure: Reconstructive Surgery Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Renal Transplantation; Mesenchymal Stem Cells Interventions: Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion; Other: Normal Saline (Placebo) Infusion Sponsors: The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine Recruiting
Conditions: Malignant Neoplasm; Oral Pain; Stomatitis Interventions: Other: Best Practice; Drug: Methylene Blue Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Glioblastoma; Gliosarcoma; MGMT-Unmethylated Glioblastoma Interventions: Radiation: Radiation Therapy; Drug: Tinostamustine Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Acute Lymphoblastic Leukemia; Allogeneic Hematopoietic Stem Cell Transplant Recipient; B Acute Lymphoblastic Leukemia; Minimal Residual Disease; Philadelphia Chromosome Positive; Recurrent B Acute Lymphoblastic Leukemia Intervention: Biological: Inotuzumab Ozogamicin Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Human Papillomavirus-16 Positive; Human Papillomavirus-18 Positive; Metastatic Malignant Neoplasm; Recurrent Anal Canal Carcinoma; Recurrent Cervical Carcinoma; Recurrent Malignant Neoplasm; Recurrent Penile Carcinoma; Recurrent Vaginal Carcinoma; Recurrent Vulvar Carcinoma; Refractory Malignant Neoplasm; Stage IV Anal Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Vaginal Cancer AJCC v8; Stage IV Vulvar Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Vaginal Cancer AJCC v8; Stage IVA Vulvar Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Vaginal Cancer AJCC v8; Stage IVB Vulvar Cancer AJCC v8 Interventions: Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457; Biological: Durvalumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Colon Adenocarcinoma; High-Frequency Microsatellite Instability; Metastatic Malignant Solid Neoplasm; Rectal Adenocarcinoma; Refractory Colorectal Carcinoma; Stage IV Colon Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8 Intervention: Biological: Anti-PD-L1/TGFbetaRII Fusion Protein M7824 Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract Interventions: Drug: Pembrolizumab; Biological: Clostridium Novyi-NT; Drug: Doxycycline Sponsors: M.D. Anderson Cancer Center; BioMed Valley Discoveries, Inc; Merck Sharp & Dohme Corp. Recruiting
Conditions: Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8 Interventions: Drug: Apalutamide; Other: Quality-of-Life Assessment; Procedure: Radical Prostatectomy Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Positive Interventions: Radiation: Radiation Therapy; Procedure: Therapeutic Conventional Surgery Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Atypical Ductal Breast Hyperplasia; Atypical Lobular Breast Hyperplasia; Ductal Breast Carcinoma In Situ; Invasive Breast Carcinoma; Lobular Breast Carcinoma In Situ Interventions: Drug: Bexarotene; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Pancreatic Ductal Adenocarcinoma; Progesterone Receptor Negative; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Lymphoma; Refractory Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm Interventions: Drug: Oxidative Phosphorylation Inhibitor IACS-010759; Other: Pharmacodynamic Study; Other: Pharmacokinetic Study Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Hepatocellular Carcinoma; Resectable Hepatocellular Carcinoma Interventions: Biological: Ipilimumab; Biological: Nivolumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Androgen Receptor Positive; Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; PTEN Positive; Recurrent Breast Carcinoma; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma Interventions: Drug: Alpelisib; Drug: Enzalutamide Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Novartis; Astellas Pharma Global Development, Inc. Recruiting
Conditions: Edema; Erythema; Peau d'Orange; Recurrent Inflammatory Breast Carcinoma; Stage IV Inflammatory Breast Carcinoma Interventions: Drug: Atezolizumab; Drug: Cobimetinib; Drug: Eribulin; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Colorectal Cancer Interventions: Behavioral: Interview; Behavioral: Questionnaire Sponsors: M.D. Anderson Cancer Center; Patient-Centered Outcomes Research Institute Recruiting
Conditions: Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands Interventions: Drug: Selumetinib; Drug: Olaparib Sponsors: M.D. Anderson Cancer Center; AstraZeneca Recruiting
Conditions: Melanoma and Other Malignant Neoplasms of Skin; Metastatic Melanoma Interventions: Drug: GSK2636771; Drug: Pembrolizumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); National Institutes of Health (NIH); Merck Sharp & Dohme Corp.; GlaxoSmithKline Recruiting
Conditions: BTK Gene Mutation; Chronic Lymphocytic Leukemia; PLCG2 Gene Mutation; Small Lymphocytic Lymphoma Interventions: Drug: Ibrutinib; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: ERBB2 Gene Amplification; Estrogen Receptor Positive; Inflammatory Breast Carcinoma; Metastatic Breast Carcinoma; Progesterone Receptor Positive; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Neratinib; Drug: Paclitaxel; Biological: Pertuzumab; Biological: Trastuzumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Puma Biotechnology, Inc. Recruiting
Condition: Prostate Carcinoma Interventions: Procedure: Bone Scan; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Magnetic Resonance Whole Body Diffusion-Weighted Imaging Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Conditions: High Risk Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia Intervention: Biological: Daratumumab Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting